Susan Molineaux

Slammed with PhII flop for lead drug, Calithera lays off a third of its staffers

Calithera Bio­sciences will be go­ing in­to the new year with on­ly two-thirds of its staff.

The South San Fran­cis­co-based biotech is lay­ing off “around 30 em­ploy­ees,” it told End­points News — or 35% of its to­tal work­force — in the wake of a Phase II flop. Adding Calithera’s tela­gle­na­s­tat to Ex­elix­is’ Cabome­tyx, the in­ves­ti­ga­tors con­clud­ed, failed to im­prove pro­gres­sion-free sur­vival for pa­tients with re­nal cell car­ci­no­ma.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.